AMOYTOP(SH:688278) Xin Lang Cai Jing·2026-01-14 07:15Group 1 - The core point of the news is that TEBIO has experienced a continuous decline in stock price, dropping 2.14% on January 14, with a total market value of 30.59 billion yuan and a cumulative decline of 11.1% over five days [1] - TEBIO specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs, with its main business revenue composition being 86.85% from antiviral drugs, 12.87% from blood/tumor drugs, and 0.27% from other supplementary products [1] Group 2 - From the perspective of TEBIO's top ten circulating shareholders, E Fund's ETF has reduced its holdings by 856,700 shares, now holding 5.881 million shares, which is 1.45% of the circulating shares, resulting in a floating loss of approximately 9.64 million yuan today [2] - The E Fund's ETF has a total scale of 76.76 billion yuan, with a year-to-date return of 9.33% and a one-year return of 55.09% [2] - The fund managers, Lin Weibin and Cheng Xi, have significant experience, with Lin managing assets totaling 122.69 billion yuan and achieving a best return of 80.47% during his tenure [2]